Literature DB >> 23204515

Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan.

Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori, Takako Miyamae, Syuji Takei, Naomi Iwata, Hiroaki Umebayashi, Takuji Murata, Mari Miyoshi, Minako Tomiita, Norihiro Nishimoto, Tadamitsu Kishimoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23204515     DOI： 10.1136/annrheumdis-2012-202310

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  15 in total

Review 1.  Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management.

Authors:  Sathish Kumar
Journal:  Indian J Pediatr       Date:  2016-02-26       Impact factor: 1.967

Review 2.  The development and assessment of biological treatments for children.

Authors:  Eve M D Smith; Helen E Foster; Michael W Beresford
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 3.  Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.

Authors:  James E Frampton
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

Review 4.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Authors:  Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan Dewitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-10       Impact factor: 4.794

5.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Authors:  Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe
Journal:  Arthritis Rheum       Date:  2013-10

Review 6.  Update on the treatment of juvenile idiopathic arthritis.

Authors:  Julia G Harris; Elizabeth A Kessler; James W Verbsky
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

Review 7.  Aryl hydrocarbon receptor and experimental autoimmune arthritis.

Authors:  Nam Trung Nguyen; Taisuke Nakahama; Tadamitsu Kishimoto
Journal:  Semin Immunopathol       Date:  2013-08-27       Impact factor: 9.623

Review 8.  Management of Juvenile Idiopathic Arthritis: A Clinical Guide.

Authors:  Štefan Blazina; Gašper Markelj; Mojca Zajc Avramovič; Nataša Toplak; Tadej Avčin
Journal:  Paediatr Drugs       Date:  2016-12       Impact factor: 3.930

Review 9.  Treatment advances in systemic juvenile idiopathic arthritis.

Authors:  Timothy Beukelman
Journal:  F1000Prime Rep       Date:  2014-04-01

Review 10.  Aryl hydrocarbon receptor antagonism and its role in rheumatoid arthritis.

Authors:  Nam Trung Nguyen; Taisuke Nakahama; Chi Hung Nguyen; Trang Thu Tran; Van Son Le; Hoang Ha Chu; Tadamitsu Kishimoto
Journal:  J Exp Pharmacol       Date:  2015-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.